1. Home
  2. FINW vs STTK Comparison

FINW vs STTK Comparison

Compare FINW & STTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo FinWise Bancorp

FINW

FinWise Bancorp

HOLD

Current Price

$18.18

Market Cap

245.2M

Sector

Finance

ML Signal

HOLD

Logo Shattuck Labs Inc.

STTK

Shattuck Labs Inc.

HOLD

Current Price

$3.05

Market Cap

119.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FINW
STTK
Founded
1999
2016
Country
United States
United States
Employees
N/A
N/A
Industry
Commercial Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
245.2M
119.0M
IPO Year
2021
2020

Fundamental Metrics

Financial Performance
Metric
FINW
STTK
Price
$18.18
$3.05
Analyst Decision
Buy
Buy
Analyst Count
2
5
Target Price
$22.00
$4.00
AVG Volume (30 Days)
22.1K
392.9K
Earning Date
01-29-2026
11-06-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
1.05
N/A
Revenue
$80,198,000.00
$1,000,000.00
Revenue This Year
$72.14
N/A
Revenue Next Year
$47.30
N/A
P/E Ratio
$17.36
N/A
Revenue Growth
14.76
N/A
52 Week Low
$13.49
$0.69
52 Week High
$22.49
$3.38

Technical Indicators

Market Signals
Indicator
FINW
STTK
Relative Strength Index (RSI) 47.23 67.21
Support Level $17.07 $2.82
Resistance Level $18.71 $3.30
Average True Range (ATR) 0.56 0.24
MACD 0.05 -0.00
Stochastic Oscillator 51.12 74.76

Price Performance

Historical Comparison
FINW
STTK

About FINW FinWise Bancorp

FinWise Bancorp is an independent bank that provides a full range of banking services to individual and corporate customers. The bank's primary source of revenue is from loans, including Small Business Administration, commercial, commercial real estate, residential real estate, and consumer. The Bank has also established Strategic Programs with various third-party loan origination platforms that use technology to streamline the origination of unsecured consumer and secured or unsecured business loans to borrowers within certain approved credit profiles.

About STTK Shattuck Labs Inc.

Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.

Share on Social Networks: